Back to top
more

Ionis Pharmaceuticals (IONS)

(Delayed Data from NSDQ)

$47.68 USD

47.68
2,110,450

-2.22 (-4.45%)

Updated Aug 30, 2024 04:00 PM ET

After-Market: $47.69 +0.01 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (94 out of 250)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

What's in the Cards for Ionis (IONS) this Earnings Season?

Ionis Pharmaceuticals, Inc. (IONS) is scheduled to report first-quarter 2017 results on May 9. Last quarter, the company recorded a positive earnings surprise of 265%. Let's see how things are shaping up for this announcement.

    Ionis Pharma Lipid Disorder Candidate Positive in Phase III

    Akcea Therapeutics, an affiliate of Ionis Pharmaceuticals, Inc. (IONS), recently announced positive results from a pivotal phase III study evaluating its pipeline candidate volanesorsen for treatment of patients with familial chylomicronemia syndrome.

      Ionis Pharmaceuticals (IONS) Beats on Q4 Earnings

      Ionis reported earnings of 21 cents including stock based compensation. However, excluding stock based compensation the company reported earnings of 33 cents that surpassed the Zacks Consensus Estimate of loss of 20 cents.

        Ionis (IONS) Q4 Earnings: What's in the Cards for the Stock?

        Ionis Pharmaceuticals, Inc. (IONS) is scheduled to report fourth-quarter 2016 results on Feb 28.

          Ionis Pharmaceuticals (IONS) Sees Hammer Chart Pattern: Time to Buy?

          Ionis Pharmaceuticals, Inc. (IONS) has been struggling lately, but the selling pressure may be coming to an end soon

            Biogen's Multiple Sclerosis Franchise to Drive Growth in 2017

            We issued an updated research report on Biogen Inc. (BIIB) on Jan 16.

              Biogen (BIIB) Presents Positive Phase III Data on Spinraza

              Biogen Inc. (BIIB) presented positive data from the phase III ENDEAR study evaluating Spinraza (nusinersen) for the treatment of spinal muscular atrophy (SMA).

                Ionis, Novartis Ink Deal to Focus on Cardiovascular Treatments

                Ionis (IONS) entered into a collaboration agreement with Novartis (NVS) for the development and commercialization of AKCEA-APO(a)-L and AKCEA-APOCIII-L.

                  Ionis (IONS) Stock Up on Positive Type II Diabetes Drug Data

                  Ionis (IONS) announced positive data from a phase II study on IONIS-GCGR for the treatment of patients with type II diabetes.

                    Company News for December 28, 2016

                    Companies in the News are: TSLA,PCRFY,IONS,TOSYY,FACU,AMZN

                      Ionis/Biogen Spinraza Approved For Spinal Muscular Atrophy

                      Ionis (IONS) and Biogen (BIIB) announced that FDA has approved Spinraza under Priority Review for the treatment of spinal muscular atrophy.

                        Ionis Receives $5 Million Milestone from J&J Unit for GI Drug

                        Ionis Pharmaceuticals, Inc. (IONS) announced that it has earned $5 million milestone payment from Janssen Biotech, Inc., a pharmaceutical division of Johnson & Johnson (JNJ).

                          Biogen Names Commercial Officer as New CEO, Shares Fall

                          Biogen Inc. (BIIB) has appointed its present chief commercial officer (CCO), Michel Vounatsos, as the new chief executive officer (CEO), effective Jan 6, 2017.

                            Ionis (IONS) Receives Milestone Payment from AstraZeneca

                            Ionis (IONS) received $28 million from AstraZeneca (AZN) following the completion of IND-supporting studies and licensing of IONIS-KRAS-2.5.

                              Kevin Matras headshot

                              Top Stocks with Big Potential Catch-Up Moves

                              Given the recent run-up in the market, here's a screen I've been using recently.